SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Mar 21

PMID 35311071

Authors

Lin Ma

Junjuan Xiao

Yaping Guan

Dongfang Wu

Tiantian Gu

Jun Wang

Affiliations

Soon will be listed here.

Abstract

Background: Rearrangements of Anaplastic lymphoma kinase () have been discovered as a novel driver mutation in patients with non-small-cell lung cancer (NSCLC). Patients' responses to ALK tyrosine kinase inhibitors (TKIs) may vary depending on the variations of rearrangements they have. It is imperative for clinicians to identify druggable fusions in routine practice.

Case Presentation: In this study, we discovered a rare rearrangement type () in a Chinese lung adenocarcinoma patient who responded well to ALK inhibitor SAF-189s. The positive expression of ALK in lung biopsy tissue was verified by IHC analysis. A new fusion was discovered using NGS. The patient was treated with SAF-189s (160 mg per day) as a first-line therapy and went into continuous remission, with a 12 months progression-free survival at the last follow-up.

Conclusion: This is the first case of fusion with an excellent response to an ALK inhibitor, which will provide better understanding of ALK-TKI applications for NSCLC patients with fusion in the future.

Citing Articles

Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired compound mutations ALK L1196M and D1203N.

Li N, Li H, Wang D, Xu X Front Pharmacol. 2023; 14:1197163.

PMID: 38149055 PMC: 10750356. DOI: 10.3389/fphar.2023.1197163.

Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple fusions treated with tyrosine kinase inhibitors.

Wei Q, Zhang Y, Wang Y, Desai A, Tan S, Huang Q Transl Lung Cancer Res. 2023; 12(9):1935-1948.

PMID: 37854161 PMC: 10579835. DOI: 10.21037/tlcr-23-484.

References

Peled N, Palmer G, Hirsch F, Wynes M, Ilouze M, Varella-Garcia M . Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012; 7(9):e14-6. PMC: 3645938. DOI: 10.1097/JTO.0b013e3182614ab5. View

Golding B, Luu A, Jones R, Viloria-Petit A . The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018; 17(1):52. PMC: 5817728. DOI: 10.1186/s12943-018-0810-4. View

Guo H, Duyzend M, Coe B, Baker C, Hoekzema K, Gerdts J . Genome sequencing identifies multiple deleterious variants in autism patients with more severe phenotypes. Genet Med. 2018; 21(7):1611-1620. PMC: 6546556. DOI: 10.1038/s41436-018-0380-2. View

Pisapia P, Pepe F, Baggi A, Barberis M, Galvano A, Gristina V . Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. Crit Rev Oncol Hematol. 2021; 169:103525. DOI: 10.1016/j.critrevonc.2021.103525. View

Rokutan H, Hosoda F, Hama N, Nakamura H, Totoki Y, Furukawa E . Comprehensive mutation profiling of mucinous gastric carcinoma. J Pathol. 2016; 240(2):137-48. DOI: 10.1002/path.4761. View

Zhao Y, Yang J, Chen Z, Gao Z, Zhou F, Li X . Identification of somatic alterations in stage I lung adenocarcinomas by next-generation sequencing. Genes Chromosomes Cancer. 2014; 53(4):289-98. DOI: 10.1002/gcc.22138. View

Hallberg B, Palmer R . Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013; 13(10):685-700. DOI: 10.1038/nrc3580. View

Listi A, Barraco N, Bono M, Insalaco L, Castellana L, Cutaia S . Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer. Transl Cancer Res. 2022; 8(Suppl 1):S55-S63. PMC: 8799193. DOI: 10.21037/tcr.2018.10.04. View

Cadby G, Mukherjee S, Musk A, Reid A, Garlepp M, Dick I . A genome-wide association study for malignant mesothelioma risk. Lung Cancer. 2013; 82(1):1-8. DOI: 10.1016/j.lungcan.2013.04.018. View

10.

Yamagata M . Structure and Functions of Sidekicks. Front Mol Neurosci. 2020; 13:139. PMC: 7479261. DOI: 10.3389/fnmol.2020.00139. View

11.

Russo A, Incorvaia L, Del Re M, Malapelle U, Capoluongo E, Gristina V . The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. ESMO Open. 2021; 6(3):100164. PMC: 8182269. DOI: 10.1016/j.esmoop.2021.100164. View

12.

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

13.

Ramalingam S, Owonikoko T, Khuri F . Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011; 61(2):91-112. DOI: 10.3322/caac.20102. View

14.

Gristina V, La Mantia M, Iacono F, Galvano A, Russo A, Bazan V . The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. Pharmaceuticals (Basel). 2020; 13(12). PMC: 7766858. DOI: 10.3390/ph13120474. View

15.

Maki-Nevala S, Sarhadi V, Aija Knuuttila , Scheinin I, Ellonen P, Lagstrom S . Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing. Lung. 2015; 194(1):125-35. DOI: 10.1007/s00408-015-9814-7. View

16.

Zhang Y, Mao X, Liu X, Song R, Berney D, Lu Y . High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer. Int J Clin Exp Med. 2015; 8(9):15127-36. PMC: 4658885. View

17.

Heuckmann J, Balke-Want H, Malchers F, Peifer M, Sos M, Koker M . Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012; 18(17):4682-90. DOI: 10.1158/1078-0432.CCR-11-3260. View

18.

Camidge D, Bang Y, Kwak E, Iafrate A, Varella-Garcia M, Fox S . Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13(10):1011-9. PMC: 3936578. DOI: 10.1016/S1470-2045(12)70344-3. View

19.

Lima L, Feio-Dos-Santos A, Belangero S, Gadelha A, Bressan R, Salum G . An integrative approach to investigate the respective roles of single-nucleotide variants and copy-number variants in Attention-Deficit/Hyperactivity Disorder. Sci Rep. 2016; 6:22851. PMC: 4780010. DOI: 10.1038/srep22851. View

20.

Amacher J, Brooks L, Hampton T, Madden D . Specificity in PDZ-peptide interaction networks: Computational analysis and review. J Struct Biol X. 2020; 4:100022. PMC: 7138185. DOI: 10.1016/j.yjsbx.2020.100022. View